Evidence & regulatory context
- Mechanism
- Not recorded
- Target
- Not recorded
- Injury models
- Radiation
- Reported indication
- Not recorded
- First approval
- Not recorded
- Development stage
- In trials, not approved
- ChEMBL max phase
- 2 / 4 (development scale, not regulatory approval)
- Synonyms
- Gelsolin; Gelsolin recombinant; Recombinant human gelsolin; Rhu-pgsn; RHUPGSN
- Note
- Not recorded
Clinical trials 6
1 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.
Phase 1b Randomised, Double-blind, Placebo-controlled, Ascending Single Dose Infusion Trial of the Pharmacokinetics of Rhu-pGelsolin in Patients With Decreased Natural Gelsolin Levels
Low Gelsolin · Trauma · Infection · Burns
Enrolment: 40 · Results not recorded
A Phase 2 Randomised Double-blind Placebo-controlled Study To Evaluate The Efficacy And Safety Of Adjunctive Recombinant Human Plasma Gelsolin With Standard Care For Moderate-to-Severe ARDS Due To Pneumonia Or Other Infections
Acute Respiratory Distress Syndrome · Infections
Enrolment: 600 · Results not recorded
Double-Blind, Placebo-Controlled Study Assessing the Efficacy and Safety/Tolerability of IV Rhu-pGSN as a Pre- or Post-Exposure Intervention to Mitigate Proinflammatory Responses to Decompression After High Pressure in a Hyperbaric Chamber
Decompression Sickness
Enrolment: 36 · Results not recorded
A Phase 2 Randomised, Double-Blind, Placebo-Controlled, Proof-Of-Concept Study To Evaluate Efficacy And Safety Of Recombinant Human Plasma Gelsolin (Rhu-pGSN) Added To Standard Of Care In Subjects With Severe Covid-19 Pneumonia
Sars-CoV2
Enrolment: 64 · Results not recorded
A Double-blind, Placebo-controlled, Dose-escalation Study of the Safety, Pharmacokinetics, and Pharmacodynamics of Recombinant Human Plasma Gelsolin Added to Standard of Care in Subjects Hospitalised for Acute Community-acquired Pneumonia
Community-acquired Pneumonia
Enrolment: 33 · Results not recorded
Single-centre, Randomised, Double-blind, Placebo-controlled, Ascending-Dose Study to Evaluate the Safety and Pharmacokinetics of Recombinant Human Plasma Gelsolin (Rhu-pGSN) After Intravenous Administration to Healthy Volunteers
Volunteers · Healthy
Enrolment: 32 · Results not recorded
Preclinical evidence 2
1 studies reported at therapy level; 2 evidence entries itemised.
MouseRadiationMaleAdministration to irradiated mice (route not stated)After radiation exposure
Model: Acute high-dose whole-body caesium-137 gamma irradiation; parallel in vitro irradiation of human intestinal epithelial cells
Irradiation lowered plasma gelsolin and raised cytoplasmic gelsolin dose dependently. Recombinant human plasma gelsolin improved prothrombin time and activated partial thromboplastin time, raised glutathione and lowered malondialdehyde, indicating improved antioxidant status.
Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.
MouseRadiation
Extraction: mesh. Machine-extracted fields require source verification.
